

Table S1. Clinical features of Sézary syndrome patients

Patient	Sex / Age (y)	Symptoms	Duration (Mo)	SC (%)	CD158k+ PBL (%)	Previous treatment	Treatment	Outcome
1	F/69	Erythematous plaques	2	12	16	None	TM, PUVA then Ch+CS,	PR
	F/70	Erythroderma	16	30	32	TM, PUVA, CS, Ch,	Ch+CS then BX+IFN	PR
2	M/79	Erythroderma	48	70	90	TM, Ch, MTX	TM+Ch+MTX	PR then DOD
3	M/75	Erythroderma	60	70	80	TM, CS	Ch+TM+CS	PR then DOD
4*	M/61	Erythroderma, PPK Polyadenopathy	24	0	0	PCT	Cytapheresis+IFN then BX+IFN+PP	PR then DOD
5	F/72	Erythroderma	12	5	ND	CS	Ch+TM+CS	PR then DOD
6*	M/63	Erythroderma	108	2	ND	CS, PUVA, MTX	Ch+CS then IFN	PR
	M/66	Erythematous plaques	138	2	ND	Ch, CS, PUVA, MTX, IFN	CS+MTX+BX	PR
7	M/67	Erythroderma, PPK	12	12	ND	None	TM+CS	CR
8	F/75	Erythroderma	0.5	22	ND	CS	Ch+TM+CS	PR
9	M/77	Erythematous plaques	7	15	ND	None	Ch+TM+CS	P
	M/78	Erythematous plaques	18	12	ND	Ch, TM, CS, MTX, CPM	PUVA	P
10	F/77	Erythroderma	60	20	ND	None	PUVA+CS+BX	PR then DOD

y, year(s); mo, month(s); SC, Sézary cells; PBL : peripheral blood lymphocytes; M, male; F, female; PPK : palmoplantar keratosis; ND, not done; TM, topical mechlorethamine; PUVA, psoralen UVA photochemotherapy; Ch, chlorambucil; CS, corticosteroid; MTX, methotrexate; IFN, interferon α ; CPM, cyclophosphamide; PP, photopheresis; BX, bexarotene; PR, partial remission; DOD, dead of disease; and P, progression.

* Data at the stage of partial remission under treatment with PCT for patient 4 and IFN α for patient 6.